Two Chokepoints at Once: How the Hormuz Closure Compounds Thailand's Pharmaceutical Cold Chain Risk

For the past 18 months, pharmaceutical logistics planning has been shaped by one primary disruption: Houthi attacks in the Red Sea forcing vessels to reroute around the Cape of Good Hope, adding 10 to 14 days to Europe-bound transits and eliminating the cost and time advantages that Suez Canal routing provided. Shipping companies adapted. Cold chain operators revised their transit time assumptions. Quality teams updated GDP documentation protocols.

Since March 2026, that calculation changed. The Strait of Hormuz has been closed following US-Israeli airstrikes on Iran, adding a second simultaneous disruption that is structurally different from the Red Sea situation and that compresses the routing alternatives for Thai pharmaceutical exporters to Europe. Understanding both disruptions, their current status, and what they mean for cold chain compliance is no longer optional planning work. It is operational necessity.

The Hormuz Closure: What Happened and Why It Is Different

On February 28, 2026, US and Israeli forces conducted airstrikes on Iran, an operation referred to in reporting as Operation Epic Fury. Iran confirmed the closure of the Strait of Hormuz between March 2 and 4, 2026. Maersk, Hapag-Lloyd, and CMA CGM all suspended Strait transits and rerouted around the Cape of Good Hope. The Iran airspace was also closed to commercial traffic, affecting air cargo routing on routes that had previously overflown Iran between Europe and Asia.

The Strait of Hormuz is not primarily a container shipping chokepoint the way the Suez Canal is. It is an energy chokepoint. According to the US Energy Information Administration, approximately 20 million barrels per day of petroleum liquids transited the Strait in 2024, representing roughly 20% of global petroleum liquids consumption. The International Energy Agency places the figure closer to 25% of world seaborne oil trade. These are different denominators, not contradictory estimates. The common point is that Hormuz closure creates energy supply disruption at a scale that Houthi attacks in the Red Sea never did, because the Red Sea disruption affected container cargo while Hormuz affects oil supply chains that underpin petrochemical-dependent manufacturing globally.

For pharmaceutical logistics, the Hormuz closure matters in three specific ways that the Red Sea disruption did not. First, pharmaceutical active ingredient supply chains from India and China that route through the Persian Gulf are directly affected. India exports significant volumes of APIs through Gulf ports and air hubs. Extended Hormuz closure raises API delivery timelines and costs for European finished drug manufacturers, creating upstream supply pressure even for products that have no direct relationship with Middle Eastern trade routes. Second, the air freight dimension is distinct. Iran airspace closure forces aircraft on Europe-to-Southeast Asia routes onto longer paths over Central Asia or the Gulf states, adding transit time and cost to temperature-sensitive air cargo. Third, the insurance treatment of a military closure differs from attack-risk disruption: war risk premiums for vessels operating near the Strait have implications for cost structures that differ from the Houthi attack-risk premiums that shaped Red Sea routing decisions.

The Red Sea Status: Where Things Stand in June 2026

The Red Sea situation has partially improved but not resolved. A Houthi ceasefire reduced attack frequency dramatically: roughly 7 confirmed attacks in all of 2025 compared to approximately 150 in 2024. Suez Canal traffic has partially recovered in response, but as of mid-2026 it remains approximately 60% below 2023 levels.

The reason recovery is incomplete despite the ceasefire is largely structural. Shipping companies that rerouted their operations and networks around the Cape of Good Hope rebuilt their scheduling, port call sequences, and customer commitments around the longer route. Rebuilding confidence in the Suez route and unwinding those network changes takes sustained security stability and time. Operators who planned around the Cape route during 2024 and 2025 are not going to switch back to Suez-via-Red-Sea routing on the basis of a partial ceasefire and reduced attack frequency. They need evidence of durable stability before absorbing the operational disruption of switching again.

The practical consequence is that the 10 to 14 day transit addition for Europe-bound sea cargo that characterised 2024 and 2025 is still the operative assumption for most sea freight from Thailand to Europe in mid-2026.

Why Two Simultaneous Disruptions Create a Different Risk Tier

A pharmaceutical cargo shipment from Bangkok to Hamburg historically had one primary chokepoint decision point: Suez Canal transit versus alternative routing. Before 2024, that decision was straightforward: Suez was faster, cheaper, and operationally standard. Post-2024, the decision became: Cape of Good Hope rerouting versus risk acceptance on the Red Sea route.

In 2026, the environment is different again. The Red Sea remains operationally uncertain. The Hormuz closure affects air corridors and creates upstream pressure on API supply chains. There is no single routing workaround that restores pre-2024 conditions. The combination means that operators who had adjusted their cold chain protocols for single-disruption Red Sea conditions may have under-calibrated for the compounding effect of both disruptions operating simultaneously.

For sea freight, the Cape of Good Hope route around Africa remains the primary workaround for both disruptions. For air freight, the question is whether the carrier is routing over Central Asia or through Gulf state hubs, and whether the additional flight distance and time has been factored into temperature excursion planning for the specific shipment. For API supply chains, the question is whether your European manufacturing partners have buffer stock or are operating lean against Indian and Chinese API deliveries that may be running 2 to 4 weeks later than pre-2026 baselines.

GDP Documentation When Transit Times Exceed Specification

EU GDP guidelines, as codified in the Official Journal of the European Union (2013/C 343/01), require that medicinal products be transported under conditions that meet their specification, with records maintained to demonstrate compliance throughout. When geopolitical disruptions cause transit times to materially exceed the planned duration that was used to validate temperature control for a shipment, the GDP documentation obligation does not disappear. It intensifies.

A shipment planned for 18 to 22 days of sea transit that takes 30 to 36 days via Cape of Good Hope routing is not automatically out of GDP compliance. Temperature specification compliance is about product integrity, not calendar time. But the receiving Qualified Person is required to review all available data and certify that the batch meets its specification before releasing it for pharmaceutical distribution. An extended-transit shipment that arrives with a clean, complete temperature record from a single-use data logger covering the full journey, plus a deviation report explaining why transit exceeded the planned duration, gives the QP the documentation needed to make that assessment. A shipment that arrives with incomplete temperature records, a reusable logger whose calibration has questions, or no transit deviation narrative creates a product hold and a documentation remediation exercise.

The minimum documentation package for GDP-compliant pharmaceutical shipments with extended transit times includes the complete temperature and humidity record from origin facility to destination receipt, a written deviation report explaining the cause and duration of any transit time exceedance against planned specification, a mean kinetic temperature calculation if the product operated near its storage limit during the extended period, and a risk assessment or QP notation justifying release despite the deviation. None of this is new GDP requirement. All of it is more likely to be triggered by a 30-day transit than a 20-day transit, and every exporter who has been planning on 2024-era transit time assumptions should revisit those assumptions now.

What Thai Exporters Should Do

The practical response to dual chokepoint disruption is not alarm. It is an audit of current operating assumptions against the new baseline and an update where the gap is material.

Review the transit time assumptions embedded in your current GDP temperature control protocols. If those protocols were written or validated before 2024 using Suez Canal transit times, they are operating against a baseline that no longer exists. If they were updated in 2024 or 2025 for Cape of Good Hope rerouting but have not been reviewed since the Hormuz closure, they may need further adjustment for air freight and upstream API supply considerations.

Confirm data logger deployment standards for every active pharmaceutical shipment to Europe. Single-use loggers with factory-issued calibration certificates are the appropriate tool for extended-transit GDP-compliant shipments. A logger that was calibrated before deployment and covers the full transit time without ambiguity about which shipment the record corresponds to is the minimum standard a receiving QP will accept. Reusable loggers with calibration uncertainty or previous deployment history create documentation questions that pharmaceutical importers do not want to address at batch release time.

Review your freight insurance coverage specifically for Hormuz military closure versus Red Sea attack risk. These are different insurance events with different policy triggers, and coverage that was structured around Houthi attack risk may not respond identically to Iran's military closure of the Strait.

DeeMED handles GDP-compliant logistics coordination for medical cannabis and pharmaceutical exports from Thailand, including single-use data logger deployment through our Frigga distributor relationship and documentation support for deviation management. If your current cold chain protocols need a review against the 2026 disruption baseline, reach out directly.